Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxecitine SCHEMBL29910618 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL30616799 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL15832461 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL10238960 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL31503186 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23346798 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL13700553 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL23178 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL193815 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB | |
| Doxecitine SCHEMBL2623809 | 1.00 | DNMT1 (0.66) | DNMT1ADRB1POLBLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995794-B | Cyclodextrin porous liquid material and application thereof | 中国石油大学(华东) | 2022-07-29 | — | — | CN | claimed |
| CN-119730857-A | Method for improving bioavailability of nucleoside drug substance | 优西比生物科学股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240016938-A1 | METHODS FOR INCREASING THE BIOAVAILABILITY OF NUCLEOSIDE MEDICINAL AGENTS | UCB BIOSCIENCES, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| CN-111995794-B | Cyclodextrin porous liquid material and application thereof | 中国石油大学(华东) | 2022-07-29 | — | — | CN | disclosed |
| EP-3885437-A1 | DNA-ENCODED CHEMICAL LIBRARY, USE THEREOF, AND METHOD TO SYNTHESIZE THE LIBRARY | Technische Universität Dortmund (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-10000801-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000801-B2 | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-7723495-B2 | Amidite for nucleic acid synthesis and nucleic acid synthesizing method | FUJITSU LIMITED (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | DEITERS ALEXANDER | 2010-04-22 | — | — | US | disclosed |
| US-20100092952-A1 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | FUJITSU LIMITED (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1402024-B1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION AS (DK) | 2007-08-22 | — | — | EP | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | RNGTT, NT5C3B, ADAR | DNMT1 145/4885ADRB1 3077/4885POLB 60/4885 |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | DNMT1 1747/4885ADRB1 2845/4885POLB 911/4885 |
| US-20240016938-A1 | METHODS FOR INCREASING THE BIOAVAILABILITY OF NUCLEOSIDE MEDICINAL AGENTS | OAT, NME4, TK2 | DNMT1 357/4885ADRB1 3077/4885POLB 197/4885 |
| US-20180153916-A1 | ISOTOPOLOGUES OF 5-AZACYTIDINE | UNG, DCTD, DPYD | DNMT1 13/4885ADRB1 3825/4885POLB 109/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | DNMT1 2468/4885ADRB1 583/4885POLB 606/4885 |
| US-20090062521-A1 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID | NSUN2, RNMT, ADAR | DNMT1 103/4885ADRB1 4595/4885POLB 185/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | DNMT1 303/4885ADRB1 3502/4885POLB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.